COO Stock Chart & Stats
$1243.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1243.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$880.00 - $6,046.90
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
$212.74B
Enterprise Value$16.38B
Total Cash (Recent Filing)$154.70M
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)20.3
Beta0.22
Next Earnings
Dec 03, 2026EPS Estimate
19.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.93
Shares Outstanding190,155,290
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio-8.14
Price to Book (P/B)1.70
Price to Sales (P/S)3.42
P/FCF Ratio32.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,224.19Price Target Upside-1.51% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)88.37
Revenue Forecast (FY)$82.82B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue expansion indicates continued demand across Cooper’s women’s health and vision-care businesses. A growing top line provides a durable base for operating leverage, product investment and broader customer penetration, provided management can convert sales growth into stronger profitability.
Conservative Balance SheetLow and improving leverage gives Cooper financial flexibility to fund research, commercial expansion and strategic initiatives without relying heavily on additional borrowing. The stronger equity base also improves resilience when margins or cash generation are under pressure.
Fertility Growth And InnovationBroad-based fertility momentum supports a durable growth opportunity beyond individual product cycles. Market-share gains, expanding clinic relationships and continued product and service launches can deepen customer integration and strengthen CooperSurgical’s position as fertility access and treatment utilization expand.
Bears Say
Leadership TransitionA sudden CEO departure and interim leadership arrangement create execution and strategic-continuity risk during an important period of commercial investment. The board search may ultimately strengthen leadership, but the transition could delay decisions or unsettle operating priorities over the coming quarters.
Compressed Operating MarginsThe sharp profitability contraction shows that revenue growth is not currently translating efficiently into operating earnings. Continued commercial investment, foreign-exchange pressure and higher costs could keep margins below prior levels, limiting earnings quality and reducing funds available for reinvestment.
Weak Cash ConversionA steep decline in operating and free cash flow weakens the company’s ability to self-fund growth and capital returns, even with a conservative balance sheet. Cash flow covering only about half of net income also indicates materially weaker earnings conversion that requires sustained improvement.
Cooper Co News
COO FAQ
What was Cooper Co’s price range in the past 12 months?
Cooper Co lowest stock price was $880.00 and its highest was $6046.90 in the past 12 months.
What is Cooper Co’s market cap?
Cooper Co’s market cap is $212.74B.
When is Cooper Co’s upcoming earnings report date?
Cooper Co’s upcoming earnings report date is Dec 03, 2026 which is in 33 days.
How were Cooper Co’s earnings last quarter?
Cooper Co released its earnings results on Sep 09, 2026. The company reported $21.486 earnings per share for the quarter, beating the consensus estimate of $21 by $0.486.
Is Cooper Co overvalued?
According to Wall Street analysts Cooper Co’s price is currently Overvalued.
Does Cooper Co pay dividends?
Cooper Co does not currently pay dividends.
What is Cooper Co’s EPS estimate?
Cooper Co’s EPS estimate is 19.95.
How many shares outstanding does Cooper Co have?
Cooper Co has 190,155,290 shares outstanding.
What happened to Cooper Co’s price movement after its last earnings report?
Cooper Co reported an EPS of $21.486 in its last earnings report, beating expectations of $21. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cooper Co?
Currently, no hedge funds are holding shares in MX:COO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,224.19 (-1.51% Downside)
$1,224.19 (-1.51% Downside)
Blogger Sentiment
Neutral
MX:COO Sentiment 50%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth $10.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.06%
12-Months-Change
Fundamentals
Return on Equity
6.88%
Trailing 12-Months
Asset Growth
2.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cooper Co
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
COO Company Deck
COO Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: the company delivered an earnings beat, record quarterly free cash flow, an 86% year-to-date free cash flow increase, a favorable tax resolution, substantial share repurchases and continued fertility and product momentum. These strengths were tempered by flat CooperVision revenue, U.S. channel destocking that will continue into Q4, legacy hydrogel declines, China and Asia Pacific challenges, near-term margin pressure and a higher expected fiscal 2027 tax rate. Management expressed confidence that inventory actions will be completed in Q4 and that increased commercial investment will support improved growth.View all MX:COO earnings summariesCOO Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
COO Stock 12 Month Forecast
Average Price Target
$1,224.19
▼(-1.51% Downside)
Technical Analysis
Baxter International
―
Merit Medical Systems
―
Staar Surgical
―
Teleflex
―
Bausch + Lomb Corporation
―